Prospera Financial Services Inc Acquires 275,104 Shares of Novo Nordisk A/S $NVO

Prospera Financial Services Inc raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 267.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 378,006 shares of the company’s stock after acquiring an additional 275,104 shares during the quarter. Prospera Financial Services Inc’s holdings in Novo Nordisk A/S were worth $26,091,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in NVO. Jennison Associates LLC grew its stake in Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after purchasing an additional 63,341 shares during the last quarter. Kingstone Capital Partners Texas LLC boosted its holdings in shares of Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after buying an additional 10,001,898 shares in the last quarter. Folketrygdfondet grew its position in shares of Novo Nordisk A/S by 6.9% in the 1st quarter. Folketrygdfondet now owns 9,521,912 shares of the company’s stock worth $661,202,000 after buying an additional 617,974 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Novo Nordisk A/S by 11.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,692,554 shares of the company’s stock worth $395,291,000 after acquiring an additional 576,900 shares in the last quarter. Finally, Sustainable Growth Advisers LP boosted its stake in Novo Nordisk A/S by 3.8% in the first quarter. Sustainable Growth Advisers LP now owns 5,543,246 shares of the company’s stock valued at $384,923,000 after acquiring an additional 202,443 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 1.9%

Shares of NVO stock opened at $45.62 on Friday. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $112.52. The firm has a market capitalization of $203.69 billion, a PE ratio of 12.53, a P/E/G ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The stock’s 50-day simple moving average is $55.32 and its 200-day simple moving average is $61.49.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on NVO shares. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target on the stock in a research note on Wednesday, August 13th. Finally, HSBC set a $70.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $59.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.